239 related articles for article (PubMed ID: 31512069)
1. A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction.
Hansen SA; Aas E; Solli O
Eur J Health Econ; 2020 Feb; 21(1):73-84. PubMed ID: 31512069
[TBL] [Abstract][Full Text] [Related]
2. A systematic review assessing the economic impact of sildenafil citrate (Viagra) in the treatment of erectile dysfunction.
Martin AL; Huelin R; Wilson D; Foster TS; Mould JF
J Sex Med; 2013 May; 10(5):1389-400. PubMed ID: 23347555
[TBL] [Abstract][Full Text] [Related]
3. Incremental cost-effectiveness of various monthly doses of vardenafil.
Aspinall SL; Smith KJ; Cunningham FE; Good CB
Value Health; 2011 Jan; 14(1):97-101. PubMed ID: 21211491
[TBL] [Abstract][Full Text] [Related]
4. [Do phosphodiesterase type 5 inhibitors generics enhance discontinuation due to price with patients suffering from erectile dysfunction?].
Baydaroglu E; Eschwège P; Hubert J; El Osta R
Prog Urol; 2019; 29(6):326-331. PubMed ID: 31151915
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
Cui Y; Liu X; Shi L; Gao Z
Andrologia; 2016 Feb; 48(1):20-8. PubMed ID: 25684196
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase type 5 inhibitor treatment for erectile dysfunction in patients with end-stage renal disease receiving dialysis or after renal transplantation.
Lasaponara F; Sedigh O; Pasquale G; Bosio A; Rolle L; Ceruti C; Timpano M; Negro CL; Paradiso M; Abbona A; Segoloni GP; Fontana D
J Sex Med; 2013 Nov; 10(11):2798-814. PubMed ID: 23346948
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
[TBL] [Abstract][Full Text] [Related]
8. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J
J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction: Pharmacology and Clinical Impact of the Sildenafil Citrate Orodispersible Tablet Formulation.
Scaglione F; Donde S; Hassan TA; Jannini EA
Clin Ther; 2017 Feb; 39(2):370-377. PubMed ID: 28139291
[TBL] [Abstract][Full Text] [Related]
10. Management of ED under the "severe distress" criteria in the NHS: a real-life study.
Mohee A; Bretsztajn L; Storey A; Eardley I
J Sex Med; 2014 Apr; 11(4):1056-1062. PubMed ID: 24382018
[TBL] [Abstract][Full Text] [Related]
11. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.
Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G
J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626
[TBL] [Abstract][Full Text] [Related]
12. Comparison of phosphodiesterase type 5 (PDE5) inhibitors.
Wright PJ
Int J Clin Pract; 2006 Aug; 60(8):967-75. PubMed ID: 16780568
[TBL] [Abstract][Full Text] [Related]
13. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
[TBL] [Abstract][Full Text] [Related]
14. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
[TBL] [Abstract][Full Text] [Related]
15. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
Gacci M; Andersson KE; Chapple C; Maggi M; Mirone V; Oelke M; Porst H; Roehrborn C; Stief C; Giuliano F
Eur Urol; 2016 Jul; 70(1):124-133. PubMed ID: 26806655
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.
Corona G; Mondaini N; Ungar A; Razzoli E; Rossi A; Fusco F
J Sex Med; 2011 Dec; 8(12):3418-32. PubMed ID: 21995676
[TBL] [Abstract][Full Text] [Related]
17. A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy.
Kim ED; Seftel AD; Goldfischer ER; Ni X; Burns PR
J Sex Med; 2014 Mar; 11(3):820-30. PubMed ID: 23841532
[TBL] [Abstract][Full Text] [Related]
18. Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
Hsu JC; Tang DH; Lu CY
Int J Clin Pract; 2015 Apr; 69(4):436-43. PubMed ID: 25311239
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction in Patients with Spinal Cord Trauma: Systematic Review and Meta-Analysis.
García-Perdomo HA; Echeverría-García F; Tobías A
Urol Int; 2017; 98(2):198-204. PubMed ID: 27509143
[TBL] [Abstract][Full Text] [Related]
20. New treatment options for erectile dysfunction in patients with diabetes mellitus.
Basu A; Ryder RE
Drugs; 2004; 64(23):2667-88. PubMed ID: 15537369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
